Brittany Curry
Primary Care · San Antonio, TXNPI 1790223741
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 190 payments — averaging $19.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$842
- Amgen$761
- AbbVie$309
- Lilly USA, LLC$305
- GSK$209
- Pfizer$182
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,71598%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 44 | $842 |
| Amgen | 36 | $761 |
| AbbVie | 14 | $309 |
| Lilly USA, LLC | 19 | $305 |
| GSK | 11 | $209 |
| Pfizer | 10 | $182 |
| AstraZeneca | 9 | $178 |
| Esperion Therapeutics, Inc. | 3 | $155 |
| Sumitomo Pharma America, Inc. | 8 | $144 |
| Astellas Pharma US Inc | 5 | $126 |
| Merck | 5 | $96 |
| Bayer | 4 | $82 |
| Abbott | 3 | $46 |
| Nestle Healthcare Nutrition Inc. | 2 | $42 |
| Exact Sciences | 2 | $39 |
| Corcept Therapeutics | 2 | $37 |
| Idorsia Pharmaceuticals US Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Lupin Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,776 in reported general payments places this provider in the 90th percentile of 563 primary care providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $122,748 |
| JardianceEmpagliflozin | 80 | $120,739 |
| TrulicityDulaglutide | 55 | $68,654 |
| MounjaroTirzepatide | 35 | $36,794 |
| ProliaDenosumab | 11 | $18,980 |
| MyrbetriqMirabegron | 17 | $12,163 |
| XareltoRivaroxaban | 14 | $10,203 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $9,162 |
| FarxigaDapagliflozin Propanediol | 11 | $6,539 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $2,943 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,290 |
| Levothyroxine Sodium | 95 | $1,992 |
| Ventolin HfaAlbuterol Sulfate | 23 | $1,882 |
| Atorvastatin Calcium | 269 | $1,847 |
| Gabapentin | 95 | $1,730 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $842 | $122,74882 claims |
| Boehringer IngelheimJardiance | $21 | $120,73980 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $305 | $105,44990 claims |
| AmgenProlia | $761 | $18,98011 claims |
| Astellas Pharma US IncMyrbetriq | $126 | $12,16317 claims |
| Johnson & JohnsonXarelto | $19 | $10,20314 claims |
| AstraZenecaFarxiga, Symbicort | $178 | $9,48225 claims |
| GSKTrelegy Ellipta | $209 | $9,16212 claims |
| AbbVieSynthroid | $309 | $1,68720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 563 primary care providers in Texas.
Other primary care in San Antonio
- Phillip GulleySan Antonio$23K
- Charlotte BallardSan Antonio$9K
- Christopher LoganSan Antonio$8K
- Lydia Chapa WilsonSan Antonio$7K
- Jing LiSan Antonio$6K
- Lauryn SaenzSan Antonio$5K
- Martha RuizSan Antonio$3K
- Ryan WenclSan Antonio$3K
- Gabriella MutschlechnerSan Antonio$3K
- Mary GibbensHouston$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.